Moderna stock: November 18 conference follows 15%-25% outlook

Moderna will present at the Jefferies Global Health Care Conference on Wednesday, November 18, 2026, according to a Moderna press release distributed on November 10. The presentation gives investors a scheduled company event after the biotech group reported third-quarter results and updated its full-year outlook.

Results reset the financial backdrop

Moderna reported third-quarter revenue of 1.3 billion US dollars and GAAP net income of 0.2 billion US dollars for the period ended September 30, 2026. The company also reported diluted GAAP earnings of 0.38 US dollars per share in its official quarterly results.

Management raised its expected 2026 revenue growth to 15 percent to 25 percent, compared with a previous outlook of up to 10 percent growth. The company also increased its expected year-end cash and investments balance to 8.1 billion to 8.3 billion US dollars and improved its operating-expense outlook by 0.2 billion US dollars.

What investors may watch

The November 18 conference is the next scheduled opportunity for Moderna to discuss commercial execution, its mRNA platform and pipeline priorities after the quarterly update. The company has highlighted positive Phase 3 data for intismeran and the US Food and Drug Administration approval of mFLUSIVA among its latest business updates.

Moderna stock last traded at 200.60 euros on Lang & Schwarz at 17:55 CET on Sunday, November 15, 2026.

Moderna company facts

• Company: Moderna, Inc.
• ISIN: US60770K1079
• Ticker: MRNA
• Lang & Schwarz quote: 200.60 euros on November 15, 2026, at 17:55 CET
• Third-quarter revenue: 1.3 billion US dollars for the period ended September 30, 2026
• Third-quarter GAAP net income: 0.2 billion US dollars

The broader US market environment can be followed through current S&P 500 market reports.

More news and analyses on Moderna stock.